The Path To A COVID-19 Vaccine: An Interview With Dr. Kari Nadeau

It goes without saying that a vaccine for COVID-19 is one of the most important things happening in the world today. The current race for a COVID-19 vaccine spans the globe with a host of economic, investing, and social consequences hanging in the balance. The consensus believes that successful development and distribution of a COVID-19 vaccine is possible within 12-18 months, but developing a vaccine has historically been a time-consuming process, filled with sometimes deadly risk for patients as researchers navigate the complexity of the immune system.

Will the COVID-19 vaccine be more like the measles vaccine which was developed in record time? or HIV, which has evaded scientists despite years of funding? 

To help our team navigate this intricate landscape over the past few months, we have held ongoing conversations with leading vaccine experts and academic epidemiologists.  Next week, subscribers will be given the opportunity to be a part of that conversation. Please join us for a fireside chat with Dr. Kari Nadeau to discuss her outlook for a COVID-19 vaccine including the timeline, challenges, promising candidates and platforms, and the outlook for success in the near- term. Dr. Nadeau is directly involved in both public and private efforts to address the COVID-19 pandemic, and we look forward to hearing her valuable insights.

Speaker Profile

Dr. Kari Nadeau is the Naddisy Foundation Endowed Professor of Medicine and Pediatrics and, Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. She is Section Chief in Asthma and Allergy in the Pulmonary, Allergy and Critical Care Division at Stanford. She is now the Sr. Director of Clinical Research for the Division of Hospital Medicine. Dr. Nadeau leads a team of specialists spanning allergy, asthma, and immunology across Stanford University. She has been a pioneer in the field of Translational Allergy and Immunology, both defining the mechanism of new therapies and then translating them clinically to make transformative changes in patients. She has led research in oncology, transplant and autoimmune trials and is a member of the National Steering Committee for the intramural clinical research programs at the NIH. She has also started 4 biotech companies in the Bay Area under Stanford patents and has worked in industry to shepherd two drugs through the FDA to approval.

Thomas Tobin
Managing Director


Twitter
LinkedIn

Emily Evans
Managing Director – Health Policy



Twitter
LinkedIn

William McMahon
Analyst


Twitter
LinkedIn